Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.38 |
| ▸ | CTSG | P08311 | 2/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.38 |
| ▸ | CMA1 | P23946 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1126593 | 0.87 | FAAH (0.44) | KMT2AMEN1HTTL3MBTL1CTRB1 | |
| SCHEMBL21526204 | 0.87 | FAAH (0.44) | KMT2AMEN1HTTL3MBTL1CTRB1 | |
| SCHEMBL1337151 | 0.84 | HPGD (0.50) | KMT2AMEN1HTTL3MBTL1HPGD | |
| SCHEMBL17646421 | 0.79 | FOLH1 (0.56) | HTT | |
| SCHEMBL17646347 | 0.79 | FOLH1 (0.56) | HTT | |
| SCHEMBL8646560 | 0.77 | FAAH (0.45) | TSHRFAAH | |
| SCHEMBL6408059 | 0.77 | CA2 (0.36) | KMT2AMEN1JAK3BTKHPGD | |
| SCHEMBL14493635 | 0.76 | TSHR (0.43) | KMT2AMEN1HTTTSHRFAAH | |
| SCHEMBL15095738 | 0.76 | TSHR (0.43) | KMT2AMEN1HTTTSHRFAAH | |
| SCHEMBL19458516 | 0.76 | FAAH (0.32) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142668-A1 | CATHEPSIN C INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142668-A1 | CATHEPSIN C INHIBITORS | CTSE, CTSB, CTSS | KMT2A 4280/4885MEN1 4882/4885HTT 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.